Director at OnKure (NASDAQ: OKUR) receives 7,650 stock options

Rhea-AI Filing Summary

OnKure Therapeutics director Andrew John Phillips received a grant of stock options covering 7,650 shares of Class A common stock at an exercise price of $4.30 per share. The options vest 100% on the earlier of June 4, 2027 or the day before the next annual stockholder meeting, contingent on his continued service, and expire on June 3, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Phillips Andrew John

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	7,650	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 7,650 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 7,650 options Exercise price: $4.30 per share Expiration date: June 3, 2036 +1 more

4 metrics

Options granted 7,650 options Stock Option grant to director on June 4, 2026

Exercise price $4.30 per share Exercise price for 7,650 stock options

Expiration date June 3, 2036 Option term end date

Vesting date trigger June 4, 2027 or before next annual meeting 100% cliff vesting condition, subject to continued service

Key Terms

Stock Option (right to buy), Class A Common Stock, vesting, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Class A Common Stock financial

"underlying_security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

vesting financial

"100% of the shares subject to the option will vest on the earlier of June 4, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"or the day prior to the date of the Issuer's next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Phillips Andrew John

(Last) (First) (Middle)

C/O ONKURE THEREAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.3	06/04/2026		A		7,650		(1)	06/03/2036	Class A Common Stock	7,650	$0	7,650	D

Explanation of Responses:

1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

	/s/ Rogan Nunn, by power of attorney	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did OnKure Therapeutics (OKUR) report for Andrew John Phillips?

OnKure reported that director Andrew John Phillips received a grant of 7,650 stock options. These options allow him to buy Class A common shares at a fixed $4.30 exercise price as part of his equity-based compensation package.

What are the key terms of Andrew John Phillips’ 7,650 OnKure (OKUR) stock options?

The option grant covers 7,650 shares of Class A common stock at a $4.30 exercise price. All options vest together on the earlier of June 4, 2027 or the day before the next annual stockholder meeting, and expire on June 3, 2036.

When do the newly granted OnKure (OKUR) stock options to Andrew John Phillips vest?

All 7,650 options vest 100% on the earlier of June 4, 2027 or the day prior to OnKure’s next annual stockholder meeting. Vesting is conditional on Phillips continuing as a service provider through the applicable vesting date.

Is Andrew John Phillips’ OnKure (OKUR) option grant an open-market purchase or compensation award?

The Form 4 characterizes the transaction as a grant or award acquisition, not an open-market purchase. It is a stock option compensation award with a $4.30 exercise price, granted to Phillips in his capacity as a director.

How long does Andrew John Phillips have to exercise his OnKure (OKUR) stock options?

The stock options expire on June 3, 2036, giving Phillips up to roughly ten years from grant to exercise. However, he must satisfy the vesting requirement, continuing as a service provider until vesting occurs, before exercising them.